Exact claim · Version 1 · Reviewed 2026-07-23
“Afamelanotide increases pain-free light exposure in adults with EPP.”
A verdict on this wording and scope, not a universal grade for Afamelanotide.
01 · Verdict
Supported with scope
The label and randomized trials support this defined rare-disease outcome.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with a history of phototoxic reactions from erythropoietic protoporphyria.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01Afamelanotide for erythropoietic protoporphyriaPubMed · New England Journal of Medicine · Randomized trial · 2015
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.